SCT Plus Immune Therapy in Average Risk AML/MDS

Inclusion Criteria: Disease Status: * AML 1st CR with a matched family donor * AML 1st CR with unrelated donor * AML 2nd CR or CRP * MDS and \< or = 5% bone marrow myeloblasts at diagnosis Disease Immunophenotype: * Disease must express a minimum of \> or = 10% CD33 positivity for patients with AML Organ Function: * Adequate renal function, adequate liver function, adequate cardiac function, adequate pulmonary function Exclusion Criteria: * Patients with active CNS AML disease at time of preparative regimen * Secondary MDS * Poor cytogenetics * Female patients who are pregnant * Karnofsky \<70% or Lansky \<50% if 10 years or less * Age \>25 years * Seropositive for HIV